Imugene Secures $11.7m R&D Tax Refund to Boost Cancer Therapy Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 10 2025
0mins
Should l Buy ?
Source: Business Insider
Imugene Limited Update: The company has received an A$11.7 million R&D tax refund for the 2023 financial year, which will aid in advancing its immuno-oncology pipeline and strengthen its market position.
Company Overview: Imugene Limited is focused on developing innovative immunotherapies for cancer treatment, with a diverse pipeline including CAR T therapies and vaccines, and currently holds a market cap of $207.6 million.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
